Dalibor Sames
Professor of Chemistry at Columbia University
Data updated
Research Footprint
Dalibor Sames appears in 6 tracked papers (2019–2026), most studied alongside Ibogaine and 5-MeO-DMT, across Substance Use Disorders (SUD), Medicinal Chemistry & Drug Development and Depressive Disorders.
Most-cited paper: Structural pharmacology and therapeutic potential of 5-methoxytryptamines (74 citations).
Frequent co-authors: Tobias Buchborn, Deborah Mash and Ignacio Carrera.
Background & Research
Dalibor Sames is a Professor of Chemistry at Columbia University and a member of the Zuckerman Mind Brain Behavior Institute. His research combines organic synthesis, molecular design, and pharmacology to study neuroplasticity-promoting compounds, with major work on ibogaine, iboga alkaloids, tianeptine, kratom, and related CNS therapeutics. He earned his degrees at Charles University in Prague and the University of Arizona and completed postdoctoral research at Memorial Sloan Kettering Cancer Center.
Key Impact
He is a leading medicinal/organic chemist whose group has helped define the pharmacology and synthetic development of ibogaine and iboga analogs in psychedelic and neurotherapeutic research.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Dalibor Sames is associated with.
Columbia University
academicResearch with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
View stakeholder →Gilgamesh Pharma
Private BiotechGilgamesh Pharma Inc. is the post-spinoff successor of Gilgamesh Pharmaceuticals, created in October 2025 when AbbVie acquired Gilgamesh's lead asset bretisilocin (GM-2505) for up to $1.2B. Launched with over $100M in funding and retaining the original team, Gilgamesh Pharma is advancing a pipeline of rapid-acting, durable psychiatric therapeutics including blixeprodil (GM-1020), a first-in-class oral NMDA receptor antagonist. Positive Phase 2a data for blixeprodil were announced January 6, 2026, and late-stage development is planned for 2026. The company also retains an ongoing AbbVie collaboration on non-hallucinogenic neuroplastogens.
View stakeholder →